Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
125 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
"Expanded Access" [STUDY-TYPES] | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Available Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation;   Triple-Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Cisplatin;   Drug: Vinorelbine
2 Available Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Condition: Heart Decompensation
Intervention: Drug: Levosimendan
3 Available A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease
Condition: CLN2 Disease
Intervention: Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)
4 Available Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Ultratrace Iobenguane I131
5 Available Therasphere for Unresectable Primary or Secondary Liver Neoplasia
Conditions: Liver Cancer;   Liver Neoplasms;   HepatoCellular Carcinoma
Intervention: Device: TheraSphere Treatment
6 Available Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Conditions: TTR-mediated Amyloidosis;   Amyloidosis, Hereditary;   Amyloid Neuropathies, Familial;   Familial Amyloid Polyneuropathies;   Amyloid Neuropathies;   Amyloidosis, Hereditary, Transthyretin-Related
Intervention: Drug: patisiran (ALN-TTR02)
7 Available The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules
Condition: Thyroid Nodules
Intervention: Device: SWE
8 Available Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
Condition: Total Parenteral Nutrition-induced Cholestasis
Intervention: Drug: Omegaven IV lipid emulsion
9 Available Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children
Condition: Parenteral Nutrition-Associated Liver Disease
Intervention: Drug: Omegaven
10 Available cliniMACs HUD for T Cell Depletion
Condition: x Linked Combined Immunodeficiency
Intervention: Device: CliniMACs
11 Available Rivaroxaban in Mechanical Valves: RIMV Study
Condition: Thromboembolism
Intervention: Drug: Rivaroxaban
12 Available A Phase I Study of DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancers
Condition: Document Safety for DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancer
Intervention: Drug: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
13 Available Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Condition: Infantile-onset Spinal Muscular Atrophy (SMA)
Intervention: Drug: nusinersen
14 Available Early Patient Access Treatment Use Protocol CA204-220
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone
15 Available Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
Condition: Congenital Hyperinsulinism
Intervention: Drug: Pasireotide
16 Available C11 Sodium Acetate PET/CT Imaging of PCa
Condition: Prostate Cancer
Intervention: Drug: Carbon-11 Sodium Acetate
17 Available Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock
Conditions: Septic Shock;   Endotoxemia
Intervention: Device: TORAYMYXIN PMX-20R
18 Available Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
Conditions: Neoplasms;   Carcinoma, Non-Small-Cell Lung
Intervention: Drug: crizotinib
19 Available Study of Allogeneic EBV-CTLs in EBV-Associated Viremia or Malignancies
Conditions: Epstein-Barr Virus-Associated Lymphoproliferative Disorder;   Epstein-Barr Virus Lymphoma;   Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder;   Epstein-Barr Virus-Associated Viremia
Intervention: Biological: Epstein-Barr Virus Cytotoxic T Lymphoctyes (EBV-CTLs)
20 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.